NIH R01 · 2024
PROJECT SUMMARY Recent advances in cancer immunotherapies have revolutionized lung cancer treatment paradigms. However, many patients derive little or no benefit from FDA approved immune checkpoint inhibitors (ICI). A host of clinical studies have shown that pre-existing tumor-reactive T cells are critically important to achieve benefit from ICI. Therefore, augmenting the number and functionality of tumor-reactive T cells could pave the way for more effective cancer treatments. Oncolytic viruses (OVs) have been developed for their ability to specifically replicate in cancer cells leading to cancer cell lysis but not cytotoxicity towards normal cells. Recent studies indicate that stimulation…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.